AI Aids Neurologists in Telling Epilepsy from Functional Seizures

Artificial intelligence is emerging as a decision-support tool for one of clinical neurophysiology's most consequential differential diagnoses: separating epileptic seizures from functional (psychogenic nonepileptic) seizures — a distinction scalp video-EEG monitoring still gets wrong, or leaves unresolved, for a substantial share of patients referred to epilepsy monitoring units.

News-Medical reports that AI-based approaches are helping neurologists make this distinction, a task where misdiagnosis carries real costs. Patients with functional seizures are frequently treated with antiseizure medications they do not need, sometimes for years, while the underlying nonepileptic condition goes unaddressed. The gold-standard diagnostic workup — long-term scalp video-EEG with synchronized camera capture in an inpatient monitoring unit, ideally capturing one or more of the patient's habitual events — remains resource-intensive and is not universally available.

Why the epilepsy-versus-FNS distinction is hard

The two conditions can look strikingly similar at the bedside. Both produce transient behavioral changes that patients and witnesses describe as "seizures." Routine outpatient EEG, often normal or nonspecific in interictal recordings, rarely settles the question on its own.

The diagnostic burden falls on the inpatient video-EEG monitoring stay. Even with ictal recordings, readers must distinguish epileptiform patterns from artifacts, movement-related and muscle-derived signal contamination, and the postictal electrographic suppression that argues for epileptic generalized seizures. That interpretive layer — pattern recognition under time pressure — is where machine learning is now being positioned.

What AI tools are being built to do

According to the report, developers are training algorithms to detect and classify seizure-like events in EEG data, flagging features that correlate with either epileptic or functional etiology. The aim is not to replace the electroencephalographer but to provide a second layer of analysis — a triage and confidence-building instrument for clinicians reviewing long monitoring recordings.

For the reading room, the practical promise is straightforward:

• Faster review of multiday scalp video-EEG studies, where events are sparse and review time is scarce;
• A structured second opinion that may reduce diagnostic delay for functional seizure patients, who on average wait years for correct diagnosis;
• Decision support in settings without immediate access to epilepsy specialists.

Keeping claims to what the studies show

The evidence base, as summarized in the coverage, remains at the level of research demonstrations rather than established standard of care. No AI system for functional-versus-epileptic seizure classification currently holds FDA clearance as a standalone diagnostic, and clinicians should treat these tools as investigational adjuncts until validated prospectively in routine monitoring-unit workflows.

Head-to-head performance against blinded expert electroencephalographers, across diverse cohorts and recording hardware, will determine whether these classifiers earn a place next to the EEG review station.

What this means for monitoring units

For epilepsy monitoring unit teams, the near-term relevance is operational rather than disruptive. AI-assisted event detection is already familiar territory in many units; extending it toward etiologic classification — epileptic versus functional — represents a natural next step in the same pipeline.

Neurologists quoted in the coverage frame the technology as an accelerant for correct diagnosis, not a substitute for the semiological and electroclinical judgment that video-EEG correlation demands. The diagnosis of functional seizures remains one of clinical exclusion and communication, delivered to the patient with care.

As validation studies mature, the realistic trajectory is an AI flag in the reviewer's queue — a marker on candidate ictal recordings that prompts closer inspection, compresses time to diagnosis, and shortens the medication exposure of patients who never had epilepsy in the first place.